Detail akcie Biotest AG online

Business Summary: Biotest AG is a Germany-based provider of plasma proteins and biological drugs. The Company, with a chain that extends from pre-clinical and clinical development to worldwide marketing and distribution, mainly specializes in the areas of clinical immunology, hematology, and intensive care medicine. It develops, manufactures, and markets immunoglobulin, coagulation factors, and albumins based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. In addition, the Company develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus, which are produced by recombinant technologies.
Financial Summary: BRIEF: For the nine months ended 30 September 2024, Biotest AG revenues increased 11% to EUR522.7M. Net income decreased 51% to EUR29.9M. Revenues reflect Rest of the World segment increase of 2% to EUR70.5M. Net income was offset by Other Operating Income decrease of 75% to EUR6.2M (income), Administrative expenses increase of 19% to EUR27.3M (expense). Basic Earnings per Share excluding Extraordinary Items decreased from EUR1.52 to EUR0.75.